Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma (NCT04134559)
The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study
🩺 Plain-English Summary (8th-Grade Level)
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Who can join: Review the eligibility criteria below.
Location: University of California San Francisco — San Francisco, California
Age range: 0 Years to 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- University of California San Francisco — San Francisco, California
- Children's Hospital Boston — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Cincinnati Children's Medical Center — Cincinnati, Ohio
- Baylor College of Medicine — Houston, Texas
📞 Contact the Study Coordinator
Phone: (415) 476-3831
Email: arun.rangaswami@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Hepatocellular Carcinoma, Childhood clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.